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Summary
Objective: To determine the effect of matrix metalloproteinase (MMP) inhibitors in mono-iodoacetate-induced arthritis in rats.
Design: The ability of compounds to inhibit MMPs in vitro was assessed kinetically using a quenched fluorescent substrate. Rats were
injected with iodoacetate intraarticularly in one knee joint and damage to the tibial plateau was evaluated from digitized images captured
using an image analyser and by histology. Collagenase and gelatinase activity in cartilage from iodoacetate injected knees were evaluated
using 3H-rat type I collagen and gelatin zymography, respectively.
Results: Collagenase and gelatinase activity significantly increased in the knee cartilage of rats injected with iodoacetate with peak activity
by day 7. Three MMP inhibitors were examined for their efficacy in the rat iodoacetate-induced arthritis model. Significant (P<0.05) inhibition
of cartilage damage was observed in animals treated orally with 35 mg/kg b.i.d. of the three different MMP inhibitors. Inhibition of cartilage
damage by the MMP inhibitors ranged from 36–42%.
Conclusion: MMP inhibitors are partially protective against cartilage and subchondral bone damage induced by iodoacetate. These results
support an important role for MMPs in mediating the joint damage in this model of arthritis. © 2001 OsteoArthritis Research Society
International
Key words: Matrix metalloproteinase inhibitors, Iodoacetate-induced arthritis, Collagenase, Gelatinase.Received 26 October 2000; revision requested 18 January
2001; revision received 12 June 2001; accepted 25 June 2001.
Address correspondence to: Michael J. Janusz, Ph.D., Procter &
Gamble Pharmaceuticals, Inc., 8700 Mason-Montgomery Rd,
Mailbox 1069, Mason, OH 45040-9462, U.S.A. Tel: 513-622-1274;
Fax: 513-622-3681; E-mail: janusz.mj@pg.comIntroduction
Osteoarthritis (OA) is a degenerative disease that effects a
large population and results in significant morbidity and
disability. The initiating events that result in the cartilage
degradation, sclerosis of subchondral bone and osteophyte
formation that are characteristic of OA are poorly under-
stood. Numerous animal models that mimic aspects of
human OA have been developed as tools to study the
pathophysiology of the disease and to evaluate therapeutic
modalities. OA can be induced in experimental animals
by a variety of insults including surgically-induced osteo-
arthritis in dogs1, rabbits2 and guinea pigs3,4 intraarticular
injection of bacterial collagenase5 or iodoacetate6–10. In
addition, small animal models of spontaneous OA have
been described in the guinea pig11 and mouse12,13.
Matrix metalloproteinases (MMPs) have been implicated
in the cartilage matrix degradation associated with both OA
and rheumatoid arthritis (RA)14–20. Inhibition of MMPs has
long been proposed as a therapeutic modality to prevent
cartilage degradation that occurs as a result of the arthritic
process21. Numerous inhibitors of the MMPs have been
proposed as potential therapeutic agents and the various751types of compounds and their activities have been
reviewed22.
Experimental models of RA and OA have been devel-
oped to study the pathophysiology of these diseases and to
evaluate potential antiarthritic agents. However, there are
few studies on the effect of MMP inhibitors in experimental
models of arthritis. Tetracycline derivatives23 and broad
spectrum MMP inhibitors have been shown to significantly
inhibit joint swelling and bone destruction in adjuvant arthri-
tis in rats24,25. In one of these studies an MMP inhibitor was
found to significantly inhibit cartilage degradation and pan-
nus formation25. Administration of doxycycline was found to
reduce the severity of cartilage lesions and the amounts of
collagenolytic and gelatinolytic activity in cartilage extracts
from dogs with OA induced by dorsal root ganglionectomy
followed by anterior cruciate ligament transection26. How-
ever, doxycycline did not inhibit spontaneous OA in guinea
pigs whereas, a chemically modified tetracycline (CMT-7)
was effective27. Recently, the collagenase selective MMP
inhibitor, Ro 32-3555 was shown to inhibit cartilage and
bone changes that occur spontaneously in the STR/ORT
mouse28.
The use of iodoacetate to chemically induce degenera-
tive arthritis was first described by Kalbhen in chickens and
subsequently in a number of other species6–10,29. The
severity of the cartilage lesions, suppression of mobility and
inhibition of proteoglycan synthesis was directly related to
the dose of iodoacetate30. The rapid development of joint
pathology in a manner that can be controlled by the dose of
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ANIMALS
Sprague-Dawley male rats weighing 220–230 g (Harlan,
Indianapolis, IN) were housed singly in wire cages in
sanitary ventilated animal rooms with controlled tempera-
ture, humidity and regular light cycles. Rodent chow
(Ralston-Purina, Richmond, IN) and water were allowed ad
libitum. Animals were acclimated for one week before use.
It is the policy of Procter & Gamble Pharmaceuticals that
all animals be housed, fed, and handled in compliance with
the standards set forth by the Animal Welfare Act as
amended. Where standards are not indicated in the Animal
Welfare Act the recommendations on HHS Publications
(NIH) No. 85-23, Guide for the Care and Use of Laboratory
Animals were followed. The personnel at Procter & Gamble
Pharmaceuticals adhered to and were in compliance with
the above stated policy.INDUCTION OF IODOACETATE-INDUCED ARTHRITIS
Arthritis was induced by a single intraarticular injection of
iodoacetate into the knee joint of rats anesthetized using
(3:1) CO2/O2. A 10 mg/ml concentration of monosodium
iodoacetate (MIA) (Aldrich Chemical, Milwaukee, WI) was
prepared using injectable saline as the vehicle. After appro-
priate anesthesia each rat was positioned on their back and
the left leg was flexed 90° at the knee. The patellar
ligament was palpated below the patella and the injection
was made into this region. Each rat received 0.025 ml
intraarticular injection into the left knee using a glass gas
tight syringe with a 27 gauge 0.5 inch needle. Care was
taken not to advance the needle too far into the cruciate
ligaments.TREATMENTS
Animals were dosed orally with MMP inhibitor or vehicle
twice daily at 12 h intervals (b.i.d.) either for the first 7 days
after iodoacetate injection or for 21 days. Experiments
described below demonstrated that peak MMP levels were
between days 3 and 7 following iodoacetate injection.
Accordingly, a 7-day dosing protocol was developed. Data
from these experiments confirmed that dosing with a MMP
inhibitor for 7 days was almost as efficacious as adminis-
tering compound for the duration of the 21-day study.
Therefore, in experiments where compounds were
screened at a single dose, a 7-day dosing protocol was
used to reduce the amount of MMP inhibitor required,
whereas, dose response experiments were performed
using 21-day dosing. Vehicle control and MMP inhibitor
treated groups consisted of 15 animals each. Animals were
sacrificed 21 days after iodoacetate injection and the left
joint was immediately disarticulated and fixed in 10%
buffered formalin for 24–48 h prior to capturing the image.There were no deaths or observable toxic effects in any of
the animals dosed with vehicle or MMPIs.ARTICULAR CARTILAGE LESION SCORE
After fixation, an image of the tibial cartilage was cap-
tured using an Optimas image analysis system (Optimas,
Media Cybernetics LP, Silver Spring, MA). The tibial pla-
teau was utilized for image analysis because it provided a
relatively flat surface compared with the femoral condyles,
allowing the image analysis camera to focus on the entire
cartilage surface. Three independent observers assessed
cartilage damage in a blinded manner using a scale of
0–4 of increasing severity (0=normal; 4=maximum sever-
ity) (Fig. 1). The cross observer correlation was 0.83
(Pearson’s correlation coefficient). This scoring system was
similar to that described previously by Guincamp et al.30.HISTOLOGY
Knee joints were placed in 10% buffered formalin for
24 h followed by decalcification in 20% EDTA. The progres-
sion of the decalcification was assessed by X-ray and
required approximately 14–21 days. The fixed, decalcified
tissue was embedded in hard paraffin wax and was pro-
cessed using conventional dehydrating and clearing agents
and 7 M sections were cut. Sections were stained with
safranin O-fast green.
The effect of MMP inhibition on joint damage was
assessed histologically by evaluating the effect of com-
pound on the subchondral bone lesions that were charac-
terized by an infiltration by vascularized fibrous tissue and
mononuclear cells. Since the subchondral bone lesions
that occur in the rat iodoacetate model are widespread and
random, multiple sections were evaluated for each animal.
The tibial surface was cut coronally across both tibial
plateaus and the two halves were embedded into the same
paraffin block. Ten step sections 150 m apart were made
in each block providing a total of 20 samples representing
the entire tibial plateau. The mean damage score from the
20 samples from each animal (15 animals/group) was used
to determine the mean±S.E.M. for each treatment group.
Subchondral bone lesions were assessed on a scale of 0–4
where 0=no subchondral lesions with cellular infiltration,
1=minimal subchondral lesions (1–2) [for an example see
Fig. 3(f)], <5% of the tibial plateau involved, 2=mild
subchondral lesions (2–3), <15% of the tibial plateau
involved, 3=moderate subchondral lesions (4–5), <25% of
the tibial plateau involved and 4=severe subchondral
lesions (5 or more), >25% of the tibial plateau involved.
Proteoglycan content was scored in safranin O/fast
green stained slides on a scale of 0–4 where 0=no loss
of proteoglycan staining relative to a normal control,
1=minimal loss, 2=mild loss, 3=moderate loss and 4=total
loss of proteoglycan staining. A single observer performed
the histological assessment in a blinded manner.STATISTICAL ANALYSIS
Data were analysed using a non-parametric procedure
(Wilcoxon rank sum). The data are expressed as the
mean±S.E.M. and statistical differences from the vehicle
treated control (P<0.05) are denoted with an asterisk.iodoacetate injected provides a useful model system to
evaluate potential modulators of OA. In the present study
we demonstrate the up-regulation of MMPs in knee carti-
lage of iodoacetate-injected rats and the inhibition of
degenerative changes by the administration of MMP inhibi-
tors, thereby providing the first evidence that matrix metal-
loproteinases are important mediators of the joint pathology
in this model.
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Fig. 1. Macroscopic scoring of cartilage lesions. Cartilage damage was assessed from images captured and magnified using an image
analyser by three independent observers in a blinded manner using a scale of 0–4 of increasing severity (0=normal; 4=maximum severity).
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The hind limbs from rats were collected and frozen at
−70°C until processed. After thawing, the tissue surround-
ing the joint was removed, the joint was disarticulated
and the cartilage scraped from the surface of the tibia and
femur using a no. 10 scalpel blade (Bard-Parker, Becton
Dickinson, Franklin Lakes, NJ) and an illuminated magni-
fier. The cartilage chips were placed into a pre-weighed
vial, the weight of the cartilage was determined and cold
extractant was added to the vial.
Collagenase was extracted using a two step procedure.
10 l of 0.25% Triton X-100 with 0.01 M CaCl2 was added
per mg of cartilage. Extraction was performed for 20 min at
4°C followed by centrifugation in a microfuge for 20 min at
13,000 rpm. Because the cartilage slices were so thin no
homogenization was required. The supernatant was
removed and the pellet extracted with 50 mM Tris/HCl,
0.1 M CaCl2, 0.15 M NaCl, pH 7.5. The extract was heated
for 4 min at 60°C in a water bath and centrifugation
repeated as described above. The supernatant was col-
lected and combined with the supernatant from the Triton-X
100 extract.
Extraction of the gelatinases was performed by adding
30 l of 2% sodium dodecyl sulfate (SDS) per mg of
cartilage and the mixture was allowed to stand for 1 h at
4°C. The mixture was centrifuged in a microfuge for 20 min
at 13,000 rpm and the supernatant collected. This extrac-
tion and centrifugation procedure was repeated and the
supernatants combined. Preliminary experiments deter-
mined that extraction of gelatinases with SDS resulted in
better recovery of activity than extraction with 4 M GuHCL
(J. F. Woessner, unpublished observations).COLLAGENASE ASSAY
Tissue inhibitor of metalloproteinase (TIMP) present in
cartilage extracts (50 l) was inactivated by incubation with
10 l of 10 mM dithiothreitol (DTT) at 37°C for 30 min to
reduce disulfide bridges in TIMP. The DTT was inactivated
by the addition of 10 l of iodoacetamide. Telopeptide free
rat skin 3H-collagen 5.3  curie/mg in 50 mM Tris-HCl
buffer pH, 7.5 was added to give approximately
100,000 cpm of collagen. Aminophenylmercuric acetate
(APMA) was added to the reaction mixture to a final
concentration of 0.25 mM and the mixture was incubated at
30°C for 48 h. As a positive control, rat collagenase was
incubated with the collagen substrate. Collagenase diges-
tion was performed in a rigorously controlled water bath
(30°±0.1°C).GELATINASE ASSAYS
Gelatinase activity was measured by zymography using
the method of Hibbs et al.31. Briefly, dilutions of the
cartilage extract were electrophoresed on 7.5% acrylamide
gels containing 0.5 mg/ml of gelatin. The gels were washed
two times with 2.5% Triton X-100 and incubated at 37°C for
18 h in 50 mM Tris/HCl, 10 mM CaCl2, 1 M ZnCl2, 1%
Triton X-100, 0.02% NaN3, pH 7.5. The gels were then
stained with 0.1% Coomassie blue in 40% methanol for
45 min. The gels were then destained in 7% acetic acid.
Standards of recombinant MMP-2 and MMP-9 were
included in the gel. The cleared gels were scanned in a
UVP Image Capture system (UVP Inc., Upland, CA) and
the area quantified for each band (both latent and active)relative to authentic standards of MMP-2 and MMP-9. The
latent and active amounts of gelatinase were combined to
give a total value for each gelatinase.MMP INHIBITION ASSAY
The preparation of the human recombinant MMPs used
in these studies has been described previously32. MMP
inhibitors were tested for their ability to inhibit human MMPs
using the quenched fluorescence assay33. This assay was
modified to fit a 96-well format to increase the throughput.
Assays for MMPs 1, 3, 8 and 13 employed human recom-
binant truncated enzymes. MMP-7 was assayed using
recombinant catalytic domain. The optimal amount of each
enzyme to produce significant and reproducible substrate
cleavage was determined in preliminary experiments.
Assays for MMP-2 and MMP-9 utilized human recombinant
full length enzymes. MMP-2 was activated by incubating
proMMP-2 with APMA (1 mM) for 45 min. The final con-
centration of MMP-2 in the assay mixture was 1 nM.
ProMMP-9 was activated with MMP-3 (ratio 20:1) for 2 h
and diluted to a final assay concentration of 0.75 nM. The
final concentration of MMP-3 in the assay was 0.038 nM.
The low concentration of MMP-3 in the final MMP-9 dilution
did not contribute to the rate of substrate cleavage as
assessed by control experiments with 0.038 nM MMP-3.
MMPs 1, 3, 7, 8, and 13 were used at final concentrations
of 8 nM, 16 nM, 2 nM, 4 nM and 0.5 nM, respectively. The
MMP assays were performed using the fluorogenic sub-
strate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 at a con-
centration of 4 M at 25°C. The assay buffer was 50 mM
Tris, pH 7.5, 0.2 M NaCl, 5 mM CaCl2 and 0.02% Brij-35.
The increase in fluorescence due to cleavage of the sub-
strate (Gly-Leu bond) was monitored kinetically for 30
minutes with a BMG Fluostar fluorescence plate reader
(ex 328 nm, em 393 nm). Each 96-well microtiter plate
contained 100 l of substrate and 50 l of enzyme in each
well. 50 l of MMP inhibitor was added to each well (except
for positive control) to give a final volume of 200 l/well.
MMP inhibitors were tested at eight different concentrations
and an IC50 was calculated using the formula: Vi /Vo=1/
1+[I]/IC50 where Vi is the initial velocity of substrate cleav-
age in the presence of inhibitor at concentration [I] and Vo
is the initial velocity in the absence of inhibitor.ResultsDOSE AND TIME DEPENDENCE OF RAT IODOACETATE-INDUCED
ARTHRITIS
Rats were given a single intraarticular injection of various
doses of iodoacetate into the knee joint and the severity of
cartilage damage was monitored at 3 weeks, a time that
preliminary experiments had determined was sufficient for
development of cartilage damage. The severity of macro-
scopic cartilage lesions was proportional to the dose of
iodoacetate injected [Fig. 2(A)]. Mild cartilage damage was
observed at the low dose of 0.1 mg of iodoacetate (joint
score 1.1±0.04 mean±S.E.M., N=10) whereas, severe dam-
age involving the majority of the tibial plateau was observed
at the high dose of 1 mg (joint score 3.9±0.04,
mean±S.E.M., N=10). A dose of 0.25 mg was chosen for the
time course studies since this dose resulted in moderate
damage.
Osteoarthritis and Cartilage Vol. 9, No. 8 755The injection of 0.25 mg of iodoacetate into the knees of
rats resulted in a time related increase in the severity of
cartilage damage [Fig. 2(B)]. Little macroscopic damage
was observed at time points prior to one week [Fig. 2(B)].
Mild damage was observed 1 week after injection of
iodoacetate (joint score 0.9±0.2, mean±S.E.M., N=10) and
increased with time to a joint score of 2.8±0.2
(mean±S.E.M., N=10) at 3 weeks. Based on the dose
response and time course studies, a dose of 0.25 mg of
iodoacetate and 3 weeks duration was chosen to study the
effect of MMP inhibitors. This time point and dose of
iodoacetate provided sufficient cartilage damage allowing
evaluation of the efficacy of compounds in a relatively short
period of time thereby reducing the required quantity of
inhibitor.HISTOLOGICAL EVALUATION OF IODOACETATE-INDUCED ARTHRITIS
The evolution of arthritis after intraarticular injection of
0.25 mg of iodoacetate into the knee was evaluated histo-
logically. The cartilage in the knees of rats that hadreceived an intraarticular injection of 0.25 mg of iodoac-
etate 24 h prior to sacrifice showed a slight reduction in
proteoglycan staining compared to untreated controls [Fig.
3(A),(B)]. By 72 h, the cartilage of the tibial plateau was
characterized by a small central area of chondrocyte necro-
biosis and reduced proteoglycan staining. The surrounding
cartilage was swollen (i.e. its mean thickness had
increased), and there was loss of proteoglycans from the
superficial and middle zones [Fig. 3(C)].
At 1 week there was an extension of the area of central
chondrocyte necrobiosis with cartilage thinning in the sur-
rounding area, marked loss of proteoglycans and a
decreased cell density [Fig. 3(D)]. At this time the first
changes in the subchondral bone were appearing, charac-
terized by resorption below areas of cartilage necrosis
(data not shown). Three weeks after iodoacetate injection
chondrocyte necrobiosis affected all of the cartilage with
the exception of the very periphery of the articular surface
of the tibial plateau. The cartilage was thin and there was
no proteoglycan staining. There was some fibrillation of the
cartilage [Fig. 3(E), inset]. Significant remodeling of the
subchondral bone plate and calcified cartilage had
occurred. This was manifest as subchondral bone sclerosis
and deficiencies in the bone/calcified cartilage plate [Fig.
3(E),(F)]. These deficiencies contained either vascularized
cores of fibrous tissue with infiltrating mononuclear cells or
fibrocartilage. In some areas the fibrocartilage was more
myxoid extending into marrow spaces where it was associ-
ated with osteoclastic bone resorption. These resembled
the early subchondral bone cysts seen in human OA.COLLAGENASE AND GELATINASE ACTIVITY IN JOINTS OF RATS
INJECTED INTRAARTICULARLY WITH IODOACETATE
Rats were sacrificed at various times after intraarticular
injection of 0.25 mg of iodoacetate and the knee joint that
received iodoacetate was extracted as described in mate-
rials and methods. The extracts were evaluated for colla-
genase and gelatinase activity. There were detectable
levels of collagenase and gelatinase activity in control rats
that did not receive iodoacetate (Day 0) (Fig. 4). Both
collagenase and gelatinase activity increased with time
after iodoacetate injection up to day 7, after which there
was a decline in activity (Fig. 4). The increase in colla-
genase activity in rats injected with iodoacetate was stat-
istically significant at all time points tested with peak activity
4.1-fold above that of controls (Day 0) [Fig. 4(A)]. Gelati-
nase A (MMP-2) and gelatinase B (MMP-9) activity was
significantly elevated on days 7 and 21 with peak activity
at day 7 of more than three-fold above control values
[Fig. 4(B),(C)].INHIBITION OF IODOACETATE-INDUCED ARTHRITIS BY MATRIX
METALLOPROTEINASE INHIBITORS21
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Fig. 2. Dose and time dependent effect of iodoacetate injection on
the severity of damage in the knee joint of rats. The severity of
cartilage damage in the knee of rats injected with varying amounts
of iodoacetate (A) and assessed 21 days later and the effect of the
injection of 0.25 mg of iodoacetate on the severity of cartilage
damage (B) measured at varying times after injection. The data are
presented as the mean±S.E.M. from 10 rats per group.In vitro inhibitory profile of the MMP inhibitors
The MMP inhibitory profile of the compounds tested in
the rat iodoacetate-induced arthritis model are shown in
Table I. Compounds were evaluated for their ability to
inhibit human recombinant MMPs 1, 2, 3, 7, 8, 9 and 13 in
kinetic assays. Two of these compounds (PGE-6211443
and PGE-3162689) are broad spectrum inhibitors of human
MMP’s and one (PGE-6912923) is a potent inhibitor of the
deep binding pocket MMPs but spares MMPs 1 and 722.
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Osteoarthritis and Cartilage Vol. 9, No. 8 757Although PGE-6912923s selectivity against MMP-1 cannot
be evaluated in a rat model since this species lacks the
MMP-1 gene, PGE-6912923 was included in these studies
for its extremely potent inhibition of the deep pocket
MMPs.INHIBITION OF CARTILAGE DAMAGE BY MMP INHIBITORS (GROSS
PATHOLOGY)
MMP inhibitors were administered orally to rats twice
daily (35 mg/kg) during the first 7 days after iodoacetate
administration and cartilage damage was assessed at day
21. All of the MMP inhibitors significantly decreased carti-
lage damage with inhibition ranging from 36–42% (Table II).
PGE 6912923 was evaluated for its ability to inhibit
iodoacetate-induced arthritis at several doses. Admin-
istration of PGE 6912923 orally at 25, 12.5 and 5 mg/kg
twice daily for 21 days resulted in a 35%, 20% and 20%
inhibition of iodoacetate induced cartilage damage,
respectively (Table III). Inhibition of joint damage was
statistically significant (P<0.05) at all doses of PGE
6912923 tested (Table III).INHIBITION OF JOINT DAMAGE BY MMP INHIBITORS (HISTOLOGY)
The effect of PGE 6912923 on iodoacetate-induced
arthritis was evaluated histologically at day 21. Admin-
istration of PGE 6912923 orally at 25, 10 and 5 mg/kg twice
daily for 21 days resulted in a 31%, 24% and 26% inhibition
of the subchondral bone lesions, respectively. The inhibi-
tion of subchondral bone damage was statistically signifi-
cant (P<0.05) at all doses of PGE 6912923 tested (Table
III). Cartilage proteoglycan loss 3 weeks after iodoacetate
injection was also recorded. The MMP inhibitors did not
appear to protect the proteoglycan loss from cartilage as it
was virtually complete in all treatment groups with scores of
3.92, 3.89, 3.96 and 4 (scale of 0–4) for the vehicle treated
and PGE 6912923 treated (25, 10 and 5 mg/kg) groups,
respectively.Fig. 3. Time course for the development of histological lesions in the rat iodoacetate model of arthritis. Coronal section of the medial tibial
plateau: (A) 21 days after intraarticular injection of saline; (B) 1 day after injection of 0.25 mg of iodoacetate, showing a minor degree of
proteoglycan loss; (C) 3 days after the injection of iodoacetate there is cartilage swelling and significant loss of proteoglycans from the
superficial cartilage with horizontal fibrillation; (D) 1 week after injection of iodoacetate, marked loss of proteoglycan from all layers of the
cartilage, cartilage thinning, and reduction of chondrocyte numbers in the superficial zone and focally in the mid zones; (E), (F) 3 weeks after
injection of iodoacetate, the changes at this time are variable. The illustrations show the common appearances. There is widespread
chondrocyte necrobiosis and loss of proteoglycans. Occasionally the appearance of the cartilage resembles fibrillation (inset). Cartilage
thinning is sometimes extreme [left edge of (F)]. In places the calcified cartilage and subchondral bone plate are breached [(F) arrows] by
cellular infiltrates and vascularized fibrous tissue. This is associated with bone sclerosis with woven bone formation and subchondral cyst
formation. The sections were stained with Safranin O-fast green and the original magnification was ×100.21
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Fig. 4. Collagenase and gelatinase activity in joints from rats
injected intraarticularly with iodoacetate. Collagenase (A), gelati-
nase A (B) and gelatinase B (C) were measured as described in
materials and methods at various times after intraarticular injection
of iodoacetate. The data are expressed as the mean±S.D. from 5–6
rats (collagenase) and 5–7 rats for gelatinase A and B. *Denotes
significance (P<0.05) from normal uninjected control animals using
a two-sided Wilcoxon (non-parametric) test.Discussion
The matrix metalloproteinases have been implicated in
the cartilage destruction that occurs in human15,18,34 and
animal models of OA35,36. The injection of iodoacetate into
the knees of rats provides a model where lesions resem-
bling some aspects of human OA can be quickly produced
and has been suggested as a model for the study of
chondroprotective drugs8,30. The rapid development of joint
damage in the rat iodoacetate model has advantages over
spontaneous or surgical models in larger animals as
smaller amounts of inhibitor and shorter time periods are
required. In the present study we have demonstrated that
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MMP inhibition profile for compounds evaluated in the rat iodoacetate model
Compound IC50 (nM)
MMP-1 MMP-2 MMP-3 MMP-7 MMP-8 MMP-9 MMP-13
PGE-6211443 13±7 3.7±1.1 7.7±2.3 153±37 1.4±0.8 2.9±1.4 1.9±1.1
PGE-3162689 4.3±0.7 1.2±0.2 19±2.5 2.1±0.1 0.7±0.2 1.8±0.6 1.4±0.3
PGE-6912923 143±19 <0.4 12±3 3894±665 <0.4 <0.4 <0.4
Data are the mean±S.D. from 3–4 experiments.Table II
MMP inhibitors reduce cartilage damage in the rat iodoacetate
model
Compound Cartilage
lesion score
(mean±S.E.M.)
% reduction
Vehicle 2.48±0.17 —
PGE-6211443 1.6±0.18* 36
PGE-3162689 1.43±0.1* 42
PGE-6912923 1.47±0.14* 42
All compounds were dosed b.i.d. at 35 mg/kg for the first 7 days
after rats received an intraarticular injection of iodoacetate. Ani-
mals were sacrificed 21 days after receiving iodoacetate, the left
knee joint was disarticulated and the tibial plateau imaged and
scored. The data are expressed as the mean cartilage damage
score±S.E.M. from 15 animals per treatment group. *Denotes
significance (P<0.05) from vehicle.Table III
Inhibitory effect of PGE-6912923 on joint damage in the rat iodoacetate model
Compound Cartilage
lesion score
(mean±S.E.M.)
%
reduction
Subchondral
lesion score
(mean±S.E.M.)
%
reduction
Vehicle 2.37±1.9 — 2.58±0.16 —
PGE-6912923
25 mg/kg
1.53±0.14* 35 1.79±0.18* 31
PGE-6912923
12.5 mg/kg
1.9±0.22* 20 1.96±0.2* 24
PGE-6912923
5 mg/kg
1.9±0.16* 20 1.90±0.51* 26
All compounds were dosed b.i.d. for the duration of the 21-day study. Animals were sacrificed 21 days after
receiving iodoacetate, the left knee joint was disarticulated and the tibial plateau imaged and scored. Histological
sections were then prepared and scored as described in materials and methods. The data are expressed as the
mean joint damage or histology lesion score±S.E.M. from 15 animals per treatment group. *Denotes significance
(P<0.05) from vehicle.the injection of iodoacetate into the knees of rats resulted in
an increase in MMP activity. In addition, MMP inhibitors
were shown to significantly decrease the joint damage that
occurs in this model.
Increased levels of collagenase and gelatinase enzy-
matic activity were observed in cartilage extracts after
iodoacetate injection (Fig. 4). Collagenase and gelatinase
activity increased during the first 7 days after iodoacetate
injection with a decline in activity measured at day 21. We
have previously reported that significantly elevated
amounts of both MMP and aggrecanase proteoglycan
cleavage sites were detected in cartilage of rats injected
with iodoacetate by day 7 post-injection as detected using
neoepitope antibodies specific to the C terminal epitopes
DIPEN (MMP) and NITEGE (aggrecanase)37. In this study,MMP inhibitors were found to be efficacious in inhibiting
cartilage damage when dosed exclusively during the first
seven days of 21 day studies (Table II). These data suggest
that MMPs and aggrecanase are important in the early
stages of the evolution of cartilage damage in the rat
iodoacetate model.
The maximum inhibition of cartilage damage after oral
administration of an MMP inhibitor during the first seven
days after iodoacetate injection was 42%. In studies with a
number of different MMP inhibitors dosed for the entire 21
days after iodoacetate injection the maximum inhibition of
cartilage damage observed was 52% (data not shown).
These data are consistent with MMPs being important
mediators of iodoacetate-induced cartilage damage but
suggest alternative enzymes such as the cysteine protein-
ases cathepsin B38 and K39 or other mechanisms may also
contribute.
The injection of iodoacetate induces the loss of cartilage
proteoglycan as measured by safranin O-fast green stain-
ing (Fig. 3). The loss of cartilage proteoglycan staining has
been reported in guinea pigs injected with a similar dose of
iodoacetate (0.3 mg)40,41. Proteoglycan loss was followed
by a severe thinning of the cartilage and the development
of lesions in the region of the subchondral bone and
calcified cartilage consisting of fibrous tissue, infiltrating
mononuclear cells and blood vessels. Although areas
of cartilage fibrillation were observed (Fig. 3), the
subchondral/calcified cartilage lesion that is occasionally
seen in human OA as areas of neovascularization, was a
major histopathologic feature of this model at the 0.25 mg
dose of iodoacetate at 3 weeks and was inhibited by the
MMP inhibitors (Table III). The kinetics of the appearance of
the subchondral lesions correlated with the development of
the gross lesions with both becoming prominent by week 3
(Figs 2 and 3). The inhibition of the subchondral lesions as
Osteoarthritis and Cartilage Vol. 9, No. 8 759assessed by histology correlated with the inhibition of the
gross lesions as assessed by image analysis (Table III). In
addition, the administration of an MMP inhibitor for the
initial 7 days after iodoacetate injection was as efficacious
as when given for the duration of the 21-day study (Tables
II, III and unpublished observations). Therefore, we hypoth-
esize that during the first 7 days after iodoacetate injection
there is a rapid upregulation and release of metalloenzyme
activity (Fig. 4) with matrix degradation in the cartilage and
subchondral bone. The prominent subchondral lesions
seen by histology and visualized grossly by image analysis
through a greatly thinned and proteoglycan depleted matrix
develop due to cellular infiltration into the subchondral
region, possibly as an attempt at repair. MMP activity
appeared to be associated with the development of the
subchondral lesions as MMP inhibitors inhibited them.
Therefore, the rat iodoacetate model provides a rapid
method to assess potential MMP inhibitors in vivo in the
organ of interest, the joint.
The loss of cartilage proteoglycan safranin O staining
was observed after iodoacetate injection. None of the MMP
inhibitors affected this loss of proteoglycan. There could be
several reasons for the lack of proteoglycan protection by
MMP inhibitors. The proteoglycan degradation may not be
due to MMP activity. The degradation of proteoglycan in
cartilage cultures stimulated with IL-1 has been shown to
be mediated by an enzymatic activity known as ‘aggreca-
nase’ and not by MMPs42–44. Recently, in three different
animal models of inflammatory arthritis the early loss of
proteoglycan was associated primarily with aggrecanase
cleavage in the interglobulin domain45. Therefore, the loss
of proteoglycan early after the injection of iodoacetate may
be due to aggrecanase and not MMP activity and this is not
efficiently controlled by the MMP inhibitors. In fact, the
MMP inhibitors used in the present study did not inhibit IL-1
stimulated glycosaminoglycan (GAG) loss from bovine
nasal cartilage explants at concentrations as high as 25 M
(Janusz et al., unpublished data). In addition, these com-
pounds were weak inhibitors of GAG release using aggre-
canase containing supernatant prepared and assayed in a
similar manner to that previously described by Arner et al.46
(Janusz et al., unpublished data). Alternatively, the loss of
the proteoglycan matrix could be due to reduction in the
viability of the chondrocytes after iodoacetate injection. In
this scenario an MMP inhibitor would not be expected to be
of benefit.
In summary, previous studies have reported that iodo-
acetate injection into the knee of rats results in histopatho-
logical features of OA such as a loss of proteoglycan,
cartilage degeneration, osteophyte formation, a dose-
dependent reduction in spontaneous locomotion30 and
altered gait47. In the present study we have demonstrated
the important role of MMPs in the joint destruction that
occurs in the rat iodoacetate model of arthritis and the
efficacy of MMP inhibitors. The inhibition of joint damage in
this model by MMP inhibitors supports the further evalu-
ation of the therapeutic potential of MMP inhibition in
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